NCT00518726

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Surface Antigen, Inactivated, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged \> 18 years

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008	seasonal influenza vaccine 15ug

Timeline

• Start date: 2007-06-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2007-08-21
• Last updated: 2016-12-01

Locations

3 sites across 1 country: Italy